NYU study to examine investigational therapy for Gaucher disease

July 20, 2001

Enrollment underway for year-long trial

New York, NY, July 19, 2001- Researchers at NYU Medical Center have initiated a trial to study the efficacy of an investigational oral treatment for Type 1 Gaucher (go-SHAY) disease, an incurable rare genetic disorder affecting approximately 8,500 people in the U.S. The study is being conducted in the Gaucher clinic at NYU, one of the leading centers in the U.S. for the diagnosis and treatment of this disease.

"This drug has shown promise in earlier clinical evaluations conducted in Europe and Israel," said Dr. Gregory M. Pastores, Co-director of the Neurogenetics Unit at NYU School of Medicine, the study's principal investigator. "Our study was designed to provide additional information on how this new approach to managing Gaucher disease can fit in with the current treatment paradigm."

Type 1 Gaucher disease is the most common genetic disease affecting Jewish people of Eastern European (Ashkenazi Jewish) ancestry and is caused by an inherited enzyme deficiency that prevents the body from breaking down a lipid (or fat molecule) called glucocerebroside. This results in an enlargement of the liver and/or spleen, where the lipids accumulate, as well as blood-related disorders and severe bone disease. There are three known types of Gaucher disease, with Types 2 and 3 being extremely rare.

OGT-918 (Vevesca™) is an oral medication that works by inhibiting the production of the lipids associated with the disease. In contrast, the only currently approved treatment for Gaucher disease, enzyme replacement therapy (ERT), involves an intravenous (IV) infusion over the course of one to two hours usually twice per month.

OGT-918 has been studied in a total of 80 patients both in combination with ERT and as monotherapy. Oxford GlycoSciences Plc, who is developing the drug, will submit these data to the U.S. Food and Drug Administration (FDA) for marketing approval this year. The drug has received "fast track" status to expedite its review.

"The current therapy for Gaucher disease works very well for many people, but there are some who could benefit significantly from a second option," explained Robin Ely Berman, M.D., President, CEO and Medical Director of the National Gaucher Foundation (NGF).

The open-label trial, being conducted by Dr. Pastores and Dr. Edwin H. Kolodny, Chairman of the Department of Neurology at NYU, will involve 14 adult patients who have never received previous treatment with ERT or have stopped therapy for more than three months before enrollment in the study. Patients will take the medication three times a day for a period of one year and frequently be monitored to ensure the drug is safely and effectively managing their disease.
People with Gaucher disease who are interested in learning more about the trial should contact Dr. Gregory Pastores by phone at 212-263-8433 or e-mail at Gregory.Pastores@med.nyu.edu.

About New York University Medical Center NYU Medical Center is a leader in patient care, physician education and scientific research. The Medical Center is internationally renowned for excellence in areas including women's health, cardiology and cardiac surgery, minimally invasive surgery, genetics, infertility, obstetrics and gynecology. All of these areas have benefited from groundbreaking research that has been applied to clinical care.

CONTACT: Feinstein Kean Healthcare
Lauren Mazzella
P: 617-577-8110

NYU Langone Medical Center / New York University School of Medicine

Related Disease Articles from Brightsurf:

CLCN6 identified as disease gene for a severe form of lysosomal neurodegenerative disease
A mutation in the CLCN6 gene is associated with a novel, particularly severe neurodegenerative disorder.

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

Potential link for Alzheimer's disease and common brain disease that mimics its symptoms
A new study by investigators from Brigham and Women's Hospital uncovered a group of closely related genes that may capture molecular links between Alzheimer's disease and Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE, a recently recognized common brain disorder that can mimic Alzheimer's symptoms.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Tools used to study human disease reveal coral disease risk factors
In a study published in Scientific Reports, a team of international researchers led by University of Hawai'i (UH) at Mānoa postdoctoral fellow Jamie Caldwell used a statistical technique typically employed in human epidemiology to determine the ecological risk factors affecting the prevalence of two coral diseases--growth anomalies, abnormalities like coral tumors, and white syndromes, infectious diseases similar to flesh eating bacteria.

Disease-aggravating mutation found in a mouse model of neonatal mitochondrial disease
The new mitochondrial DNA (mtDNA) variant drastically speeds up the disease progression in a mouse model of GRACILE syndrome.

Human longevity largest study of its kind shows early detection of disease & disease risks
Human Longevity, Inc. (HLI) announced the publication of a ground-breaking study in the journal Proceedings of the National Academy of Sciences (PNAS).

30-year study identifies need of disease-modifying therapies for maple syrup urine disease
A new study analyzes 30 years of patient data and details the clinical course of 184 individuals with genetically diverse forms of Maple Syrup Urine Disease (MSUD), which is among the most volatile and dangerous inherited metabolic disorders.

Long-dormant disease becomes most dominant foliar disease in New York onion crops
Until recently, Stemphylium leaf blight has been considered a minor foliar disease as it has not done much damage in New York since the early 1990s.

Read More: Disease News and Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.